Wouter Plattel
dr.
As a hematologist I am always looking for new development that might improve patient care. My main research focus is on patients with Hodgkin lymphoma and multiple myeloma. I am involved in both translational and clinical studies. In cooperation with the Pathology, I am active in the field of biomarkers, such as TARC in Hodgkin lymphoma. For the design, development and execution of clinical trials, I am an active member of both international (EORTC) and national (HOVON) organizations. For example, I am the national PI of the EORTC COBRA trial in Hodgkin lymphoma. Moreover, I am co-PI of the translational research in two international trials. In addition, I am part of the Dutch guideline writing committee for Hodgkin lymphoma. In myeloma, I am investigating innovative treatment options to improve outcome.
Circulating biomarkers in classical Hodgkin lymphoma
Access to document
10.33612/diss.97631424
document
In classical Hodgkin lymphoma (cHL) there is an urgent need for biomarkers to determine prognosis or treatment response. In this thesis we summarized current knowledge on circulating biomarkers in cHL and studied a selection of these markers as treatment response or prognostic biomarkers. In the first part of this thesis we studied the application of Thymus and Activation Regulated Chemokine (TARC) as a biomarker for treatment response and compared TARC with sGal-1, sCD163 and sCD30 and interim FDG-PET imaging. We found that TARC at diagnosis correlates with metabolic...
Late onset cardiomyopathy as presenting sign of ATTR A45G amyloidosis caused by a novel TTR mutation (p.A65G)
Published in: Cardiovascular Pathology
Access to document
10.1016/j.carpath.2017.04.002
document
Objective: The clinical description of a novel TTR genemutation characterized by a late onset amyloid cardiomyopathy. Methods and Results: A 78-year-old man of Dutch origin with recent surgeryforbilateral carpal tunnel syndrome(CTS) was admitted to our hospital because of heart failure with preserved ejection fraction (55%). Cardiac ultrasound showed thickened biventricular walls, and cardiac magnetic resonance imaging also showed late gadolinium enhancement. Early signs of a polyneuropathy were found by neurophysiological testing. A few months later, his 72year- old sister was admitted to an affiliated hospital because of heart...
Sebastiaan H. C. Klaassen, Henny H. Lemmink, Johan Bijzet, Andor W. J. M. Glaudemans, Reinhard Bos, Wouter Plattel, Maarten P. van den Berg, Riemer H. J. A. Slart, Hans L. A. Nienhuis, Dirk J. van Veldhuisen, Bouke P. C. Hazenberg
Biomarkers for evaluation of treatment response in classical Hodgkin lymphoma: comparison of sGalectin-1, sCD163 and sCD30 with TARC
Published in: British Journal of Haematology
Access to document
10.1111/bjh.14317
Soluble Galectin-1 (sGal-1, also termed LGALS1), soluble CD163 (sCD163) and soluble CD30 (sCD30) have been reported to be elevated in plasma or serum of patients with classical Hodgkin lymphoma (cHL). We aimed to determine the clinical utility of these biomarkers for evaluation of treatment response compared to thymus and activation regulated chemokine (TARC, also termed CCL17). Plasma or serum samples were prospectively collected among 103 newly diagnosed cHL patients before and after treatment. Levels of sGal-1, sCD163, sCD30 and TARC were correlated with disease characteristics and clinical treatment...
Wouter J. Plattel, Zainab N. D. Alsada, Gustaaf W. van Imhoff, Arjan Diepstra, Anke van den Berg, Lydia Visser
Mid-treatment TARC and mid-treatment FGD-PET predict for progression free survival in classical hodgkin lymphom
Insulin-like growth factor 1 receptor is a prognostic factor in classical Hodgkin lymphoma
Published in: PLoS ONE
Access to document
10.1371/journal.pone.0087474
document
The interaction between the tumor cells in classical Hodgkin lymphoma (cHL) and the microenvironment includes aberrant activity of receptor tyrosine kinases. In this study we evaluated the expression, functionality and prognostic significance of Insulin-like growth factor-1 receptor (IGF-1R) in cHL. IGF-1R was overexpressed in 55% (44/80) of cHL patients. Phosphorylated IGF-1R was detectable in a minority of the IGF-1R positive tumor cells. The overall survival (OS, 98%) and 5-year progression-free survival (PFS, 93%) was significantly higher in IGF-1R positive cHL patients compared to IGF-1R negative patients (OS 83%,...
Zheng Liang, Arjan Diepstra, Chuanhui Xu, Gustaaf van Imhoff, Wouter Plattel, Anke Van Den Berg, Lydia Visser